Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

Healius Explains Late Director Notice After Adviser Platform Sells Shares Without Consent

Healius Explains Late Director Notice After Adviser Platform Sells Shares Without Consent Source: Kapitales Research

Highlights:

  • An adviser’s platform sold 8,694 Healius shares held indirectly by director Paul Anderson on 26 October 2026.

  • Mr Anderson repurchased the same number of shares on 17 November 2026, restoring his holding.

  • The company says the late disclosure is an isolated incident and that its existing policies remain appropriate.

What Happened

Healius Limited (ASX: HLS) told the market on 18 November 2026 that it was lodging a director’s interest notice, known as an Appendix 3Y, after the deadline set by the ASX Listing Rules. The notice covers director Paul Anderson, whose indirect interest is held through the Tuis Farm Family Trust, of which he is a beneficiary. Healius shares last traded at AU$0.600, up 3.448%.

The Unauthorised Sale

On 26 October 2026, an adviser’s platform sold 8,694 shares held indirectly by Mr Anderson, without his knowledge or authority. When he found out, he promptly bought back the same number of shares on 17 November 2026. The notice shows his indirect holding stands at 344,843 ordinary shares, the figure disclosed in his previous notice. His direct interests, which were not affected, include 37,837 ordinary shares, 4,469,109 performance rights and 117,433 service rights.

Why the Notice Was Late

Listing Rule 3.19A.2 requires directors’ changes in holdings to be reported within five business days. Because neither the director nor the company was told about the sale when it happened, the deadline was missed.

Company Response

Healius considers the matter an isolated incident and believes its arrangements with directors, including its policy on trading in company securities, are suitable. Mr Anderson has discussed appropriate processes with his adviser should something similar occur again. The company lodged the notice as agent for the director under section 205G of the Corporations Act. The release was authorised by the managing director and chief executive.

About Healius

Healius has operated for more than 30 years and provides specialty pathology services across Australia through its network of centres and more than 8,500 employees.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au